Pharmaceutical Executive-05-01-2009

Pharmaceutical Executive
Column

May 01, 2009

Congress-and the public-needs to take a deep breath before making a big mistake.

Pharmaceutical Executive
Features

May 01, 2009

Despite the downside in ad spend, an upside remains in the digital space that's wide open for exploration.

Features

May 01, 2009

We leap tall buildings to bring you the definitive guide to the world's top pharmaceutical companies.

Pharmaceutical Executive
Features

May 01, 2009

Al Mann has sunk almost $1 billion of his own money into a new insulin delivery system. Will FDA be persuaded?

Pharmaceutical Executive
Columns

May 01, 2009

In an era of shrinking marketing budgets, increase ROI with behavioral science-based marketing.

Pharmaceutical Executive
Features

May 01, 2009

European docs have always been down on pharma-but now the US is catching on. Perhaps pharma has oversold the "service model."

Pharmaceutical Executive
Columns

May 01, 2009

Pharma marketers face a crisis in digital media. But there's a way to turn it around.

Pharmaceutical Executive
Features

May 01, 2009

When it comes to licensing in this market, there are winners and losers. Learn the new rules of the game.

Pharmaceutical Executive
Features

May 01, 2009

Tough economic tmes call for a bold approach to evolving information technology solutions.

Pharmaceutical Executive
Columns

May 01, 2009

Marketers must stress that maintaining good health behaviors is one of the best things people can do to survive a down market.

Pharmaceutical Executive
Washington Report

May 01, 2009

Pharma fears comparative effectiveness research will focus on costs and stymie personalized medicine.

Pharmaceutical Executive
From the Editor

May 01, 2009

Our 3-D cover jumps off the page. But the real question for us (and for you) is how do we get everything else to connect?